News Channels

13 Jul 2021 Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
13 Jul 2021 ExeVir's COVID-19 antibody candidate neutralizes coronavirus Variants of Concern
13 Jul 2021 eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement
13 Jul 2021 Valo Therapeutics Announces Clinical Trial Application Submission for German Phase I Oncology Clinical Trial of PeptiCRAd-1 with Pembrolizumab
13 Jul 2021 Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
13 Jul 2021 48Hour Discovery and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals
13 Jul 2021 Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19
13 Jul 2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae
13 Jul 2021 ReiThera Announces Preliminary Phase 2 Data from its COVID-19 Vaccine Candidate
13 Jul 2021 Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
13 Jul 2021 Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas
13 Jul 2021 Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
13 Jul 2021 Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
13 Jul 2021 Janssen Announces U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
13 Jul 2021 Prothena and Novo Nordisk announce acquisition agreement for Prothena’s ATTR amyloidosis programme
13 Jul 2021 Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
12 Jul 2021 Stem cell therapy company Amniotics raises SEK 60 million in First North IPO to advance lead candidate PulmoStem™ into clinic
12 Jul 2021 Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic
11 Jul 2021 Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
11 Jul 2021 U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up